Yunnan Baiyao Group Co Ltd

Yunnan Baiyao Group Co Ltd maintains a strong liquidity position with a current ratio of 2.64, indicating the company can cover its short-term liabilities more than two times over. The company's liquidity_fpt score suggests it has sufficient cash flow to meet operational needs, although it is flagged for having negative net cash after subtracting total debt. The price-to-book ratio of 2.27 and price-to-tangible-book ratio of 2.27 suggest the company is trading at a premium to its book value, which may reflect investor confidence in its brand and product portfolio. In terms of profitability, the company's return on equity (ROE) of 12.87% and return on assets (ROA) of 9.5% are strong indicators of efficient capital use and asset management. These metrics are well above the industry median for pharmaceutical companies, which typically range between 8% and 10% for ROE and 5% to 7% for ROA. The company's gross margin of 28.9% and operating margin of 14.66% also reflect a healthy profitability profile, with both metrics exceeding the industry median. Geographically, Yunnan Baiyao Group Co Ltd is heavily concentrated in the Chinese market, with the majority of its revenue derived from domestic operations. The company has limited international exposure, which may limit its growth potential in the long term. Its product portfolio is primarily focused on TCM, which is a niche but growing segment within the broader pharmaceutical industry. The company's growth trajectory is positive, with analysts forecasting a mean price target of 70.01 CNY, significantly higher than the current market price of 50.9 CNY. The mean recommendation of 1.78, with 2 strong-buy and 7 buy ratings, indicates strong analyst confidence in the company's future performance. The company's revenue has shown consistent growth, supported by its strong brand recognition and expanding product line. Risk factors for the company include liquidity concerns due to negative net cash after subtracting total debt, which could limit its ability to invest in growth opportunities. The company's dilution risk is currently low, with no significant dilution expected in the near term. However, the company's reliance on the Chinese market and TCM products exposes it to regulatory and market-specific risks. Recent events include strong analyst sentiment, with a high number of buy and strong-buy ratings, and a positive outlook on the company's future performance. The company has not disclosed any major recent filings or transcripts that would indicate significant changes in its business strategy or financial position.